Newsroom

HMI’s subsidiary TGV-Dx wins prestigious pediatric medical device competition focused on COVID-19-related technologies

New York, NY – July 22, 2020) – A New-York city-based start-up TGV-Dx was selected a winner in the special COVID-19 edition of the “Make Your Medical Device Pitch for Kids!” competition presented by FDA-sponsored National Capital Consortium for Pediatric Device Innovation. The competition focused on innovations in COVID-19-related pediatric medical devices that will improve children’s health care, with 16 finalists competing in a virtual pitch event for a share of $250,000 in total grant awards. TGV-Dx received a grant award as a result of their winning presentation

HMI’s subsidiary TGV-DX is in final “COVID-19 edition” of pediatric medical device competition

WASHINGTONJuly 14, 2020 /PRNewswire/ — Sixteen finalists are announced in the “Make Your Medical Device Pitch for Kids!” special COVID-19 edition competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Representing innovations in COVID-19-related pediatric medical devices, the finalists will compete in a virtual pitch event held on July 20, 2020.

Interview to Forbes: SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2

Interview to Forbes : SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2

In the interview to Forbes Dr. George Tetz highlights possible major scientific breakthroughs based on his article “SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2

The full text is available at: https://www.forbes.com/sites/jvchamary/2020/04/17/prion-like-coronavirus/#6ea4b8df4680

 

Human Microbiology Institute commits expertise and assets to the fight against COVID-19 pandemic

Human Microbiology Institute commits expertise and assets to the fight against COVID-19 pandemic

New York, March 19, 2020 — Today,  Human Microbiology Institute (HMI) announced that it accelerates the development of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. HMI brings a range of breakthrough resources and expertise needed to identify novel therapeutic targets within SARS-VoC-2 for  the new solutions to the pandemic

HMI’s Discovery of Bacterial DNA as a Seed that Triggers Propagation of Tau and Development of Alzheimer’s disease will be presented at UConn 2019 Microbiome Innovation Summit

HMI’s abstract was accepted for a poster presentation at the Microbiome Innovation Summit that will be held at The Jackson Laboratory on Friday November 1, 2019 and The Jackson Laboratory in Farmington, CT.

This year’s program will feature an outstanding diversity of speakers addressing a wide range of important topics in microbiome science across many disciplines. Speakers and panel discussions will address:

  • the current landscape in microbiome research and development
  • approaches for understanding the basis of host/microbe interactions
  • best practices for experimental design and reproducibility
  • engineering of microbial systems to meet specific objectives
  • future directions in microbiome commercialization
I’m presenting at #SfN19

 

I’m presenting at #SfN19

HMI is honored to participate at the 201st Annual Meeting of the New York Academy of Sciences

HMI as a Member The New York Academy of Sciences is honored to participate at the Academy’s 201st Annual Meeting.

During the event  special guests for a by-invitation-only screening of Jim Allison: Breakthrough (2019), the inspirational story of one scientist’s quest to find a cure for cancer. Today, Academy Member James P. Allison is well-known for receiving the 2018 Nobel Prize in Physiology or Medicine jointly with Japanese immunologist Tasuku Honjo for their discovery of cancer therapies that stimulate the immune system to attack tumor cells. This gripping documentary follows Dr. Allison’s life and work over several decades, and provides insight into what it means to struggle against skepticism and resistance in order to achieve the extraordinary. A Q&A session with Bill Haney, the film’s director, was  followed the screening.

HMI’s Discovery of Previously Overseen Target to Prevent Tau Misfolding was Selected as an Oral Presentation at the Society for Neurosciences 2019

Our presentation “ Bacterial DNA promotes Tau aggregation” has been selected as an oral report at the Society for Neurosciences 2019, October 19-23, Chicago, IL.

Human Microbiology Institute Announces Oral Presentation at the SfN19

Bacterial DNA promotes Tau aggregation  

Human Microbiology Institute Research the First to Demonstrate that Bacterial DNA Trigger Alzheimer”s Disease

Research was presented at the Society for Neuroscience 2019.  Society for Neuroscience was founded in 1969 by Ralph W. Gerard and, at nearly 37,000 members, has grown to be the largest neuroscience society in the world.

Chicago, IL October 19, 2019 — Human Microbiology Institute (HMI), a not-for-profit scientific research organization, today presented data that demonstrate for the first time how microbiome can trigger Alzheimer’s disease. The study, conducted by Drs. V. and G. Tetz, in collaboration with Claudio Soto was presented by Dr. G. Tetz in an oral session at Society for Neuroscience 2019 , October 19-23, Chicago, IL.

HMI Presentation on “The American Diabetes Association’s 79th Scientific Sessions”

NEW YORK, May 01, 2019 – Human Microbiology Institute, today announced a poster presentation “A New Developmental Model of Type 1 Diabetes—An Association between Autoimmunity, the Dynamics of Gut Amyloid-Producing E. Coli, and Their Phages” at the The American Diabetes Association’s 79th Scientific Sessions  being held on June 7-11, San Francisco. The presentation includes the first microbiome-based discovery for the role of microbiome in triggering Type 1 Diabetes autoimmunity.